Treatment of mesotheliomatous pleural effusion: Experimental therapy versus thoracoscopic talc poudrage? Pro: Experimental therapy

Journal of Bronchology

Volumn 8, Issue 1, 2001, Pages 47-53

  Seijo, Luis M ^a   Sterman, Daniel H ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYTARABINE; CYTOKINE; DOXORUBICIN; GAMMA INTERFERON; GANCICLOVIR; GENE PRODUCT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2; MITOMYCIN C; PLATINUM 1,2 DIAMINOCYCLOHEXANE BISNEODECANOATE; PROTEIN HSVTK; THYMIDINE KINASE; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER CHEMOTHERAPY; DRUG DELIVERY SYSTEM; GENE THERAPY; HERPES SIMPLEX VIRUS; HUMAN; IMMUNOTHERAPY; INDWELLING CATHETER; LUNG; MESOTHELIOMA; PLEURA EFFUSION; PLEURODESIS; PRIORITY JOURNAL; REVIEW;

EID: 0035186367     PISSN: 10708030     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.lbr.0000011078.80648.a7     Document Type: Review

References (54)

1. Advances in the treatment of malignant pleural mesothelioma
2. Trials in malignant mesothelioma: LCSG 851 and 882
3. Pleurectomy/decortication and adjuvant therapy for malignant mesothelioma
4. Pleural mesothelioma
5. Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: A Lung Cancer Study Group trial
6. Malignant mesothelioma of the pleura: Review of 123 patients
7. The importance of surgical staging in the treatment of malignant pleural mesothelioma
8. Treatment and survival in diffuse malignant pleural mesothelioma: A study of 83 cases from the Massachusetts General Hospital
9. Malignant pleural mesothelioma treatment: The current state of the art
10. Malignant pleural mesothelioma: A disease unaffected by current therapeutic maneuvers
11. Diffuse malignant pleural mesothelioma: Options in surgical treatment
12. Malignant pleural mesothelioma: A survival study
13. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: A retrospective study of 332 patients
14. Malignant mesothelioma of the pleura
15. Malignant pleural mesothelioma: CT manifestations in 50 cases
16. Malignant pleural mesothelioma: A case series with prolonged survival averaging 22.4 months after treatment with thoracoscopic talc poudrage pleurodesis
17. Thoracoscopic talc poudrage pleurodesis for malignant effusions: A review of 360 cases
18. Surgery followed by intracavitary plus systemic chemotherapy in malignant pleural mesothelioma
19. Optimal management of malignant mesothelioma after subtotal pleurectomy: Revisiting the role of intrapleural chemotherapy and postoperative radiation
20. Intrapleural chemotherapy without pleurodesis for malignant pleural effusions: LCSG Trial 861
21. High doses of intrapleural cisplatin in a case of malignant pleural mesothelioma: Clinical observations and pharmacokinetic analyses
22. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma
23. Current approach to malignant mesothelioma of the pleura
24. Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: Pharmacokinetic studies
25. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions
26. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally in patients (PTS) with malignant pleural mesothelioma (MPM)
27. The role of growth factors and cytokines in the tumorigenesis and immunobiology of malignant mesothelioma
28. Altered CD3 chain and cytokine gene expression in tumor infiltrating T lymphocytes during the development of mesothelioma
29. Transforming growth factor-beta: Antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumor-infiltrating T-cells in malignant mesothelioma
30. High frequency of immune dysfunctions in asbestos workers and in patients with malignant mesothelioma
31. The alveolar macrophage: Immune derangement and asbestos-related malignancy
32. Effect of interferon-alpha 2a on malignant mesothelioma
33. Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion
34. Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma
35. Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma
36. Interleukin-2 and lymphokine-activated killer cells in malignant mesothelioma
37. Intrapleural administration of interleukin 2 in pleural mesothelioma: A phase I-II study
38. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: A Phase II study
39. Intrapleural natural beta interferon in the treatment of malignant pleural effusions
40. Intrapleural administration of tumour necrosis factor-alpha (TNFalpha) in patients with mesothelioma: Cytokine patterns and acute-phase protein response
41. Cytokine gene therapy of mesothelioma: Immune and antitumor effects of transfected interleukin-12
42. Treatment of advanced mesothelioma with the recombinant adenovirus H5.010RSVTK: A phase 1 trial (BB-IND 6274)
43. Gene therapy for malignant mesothelioma: A novel approach for an incurable cancer with increased incidence in Louisiana
44. Cytokine gene therapy or infusion as treatment for solid human cancer
45. Antiviral activity and mechanism of action of ganciclovir
46. Use of suicide genes in gene therapy
47. The role of the bystander effect in suicide gene therapy
48. Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma
49. Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: An effective in vitro drug sensitization system
50. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: Results of a phase 1 clinical trial in malignant mesothelioma
51. Impact of pre-existing and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma
52. The treatment of malignant pleural mesothelioma with gene modified cancer cells: A phase I study
53. Outpatient management of malignant pleural effusion by a chronic in dwelling pleural catheter
54. A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions